Healthcare AI
Tempus AI to Buy Cancer-Test Maker Personalis for $1.7 Billion, Betting on MRD Detection
The AI precision-oncology platform is folding tumor-informed molecular residual disease testing into its stack, chasing a US market it sizes at more than $20 billion.
Jul 21, 2026
